Incidence of colorectal lesions in first degree relatives of patients with hyperplastic polyposis syndrome (HPS)

Incidence of colorectal lesions in first degree relatives of patients with hyperplastic polyposis syndrome (HPS) - PROTECT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32126

Enrollment

Registered

2008-09-08

Start date

2008-10-27

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth tumor

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: First-degree relatives (* 35 years of age or 5 years younger than the lowest incidence age) of patients under surveillance at the Endoscopy Department of the AMC with HPS, defined as: 1) *10 HPs found at colonoscopy, or 2) *5 HPs proximal to the sigmoid colon of which 2 are greater than 10mm in diameter, or 3) Any number of HPs occurring proximal to sigmoid colon in an individual who has a first-degree relative with hyperplastic polyposis

Exclusion criteria

Exclusion criteria: Exclusion criteria are 1) individuals who have undergone a colonoscopy in the past three years 2) individuals who have undergone a colectomy 3) severe co-morbidity and 4) age less than 35 years.

Design outcomes

Primary

Measure	Time frame
The occurrence, distribution and phenotype (gross morphology, number, size, shape) of polyps and CRC in first-degree relatives of patients with HPS will be assessed. Based on these findings an estimation of the risk of developing polyps/ HPS and CRC in this group can be made so as to define whether screening of this group is justified. In addition, the proportion of individuals that complied with the screening programme will be assessed as well as the proportion of non-compliers. In these two groups, socio-demographic data and potential predictors of compliance behaviour will be compared with the higher aim of designing an effective surveillance programme for these individuals.	—

Measure

Time frame

The occurrence, distribution and phenotype (gross morphology, number, size, shape) of polyps and CRC in first-degree relatives of patients with HPS will be assessed. Based on these findings an estimation of the risk of developing polyps/ HPS and CRC in this group can be made so as to define whether screening of this group is justified. In addition, the proportion of individuals that complied with the screening programme will be assessed as well as the proportion of non-compliers. In these two groups, socio-demographic data and potential predictors of compliance behaviour will be compared with the higher aim of designing an effective surveillance programme for these individuals.

—

Secondary

Measure	Time frame
geen	—

Countries

Netherlands

Outcome results